Login to Your Account

Santhera Withdraws Raxone MAA, Plans Resubmission

By Cormac Sheridan
Staff Writer

Friday, March 22, 2013

With additional data in the offing for its Leber's hereditary optic neuropathy drug Raxone, Santhera Pharmaceuticals AG has withdrawn its marketing authorization application  from the European Medicines Agency's re-examination process and will instead submit a new file with an expanded patient database.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription